Physician profile
Fouad Chebib
NPI 1235450602
$121,986.22
in general payments reported to CMS, 2019-2025
11 companies · $42K in 2025
The $42K reported for 2025 was more than what 98% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,835 · 2020: $4,994 · 2021: $6,390 · 2022: $7,949 · 2023: $14K · 2024: $44K · 2025: $42K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $47K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $29K · Travel and Lodging: $21K · Food and Beverage: $1,383 · Honoraria: $1,175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $47,395.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $29,197.00 |
| Travel and Lodging | $20,668.80 |
| Food and Beverage | $1,383.12 |
| Honoraria | $1,175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Co., Ltd. | $45,222.78 | 2023-2025 | Jynarque |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $37,607.83 | 2021-2024 | Tolvaptan, Jynarque |
| Vertex Pharmaceuticals Incorporated | $17,741.71 | 2024 | |
| Genzyme Corporation | $7,343.78 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $6,742.51 | 2019-2024 | Jynarque |
| Astrazeneca Pharmaceuticals Lp | $4,655.00 | 2025 | |
| Hikma Pharmaceuticals USA | $2,375.00 | 2024-2025 | |
| Calliditas Therapeutics US INC. | $147.89 | 2024 | |
| Astrazeneca Uk Limited | $134.91 | 2025 | |
| Baxter Healthcare | $14.81 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fouad Chebib listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.